Abstract
Progressive dementia patients demonstrate profound and obvious learning-memory impairments. To a large extent, these are determined by failures to access and use previously learned knowledge (semantic memory) to affect encoding and processing of ongoing events (episodic memory). There are other forms of memory failures in man that are likely to be determined by quite different psychobiological mechanisms, such as failures to retain or consolidate information in memory. One important way in which drug treatments may facilitate the learning-memory impairment in mildly demented patients is by making semantic memory structures more accessible. Patients treated with 1-desoamino-8-D-arginine vasopressin (DDAVP), a synthetic analog of the hypothalmic peptide arginine vasopressin, demonstrate cognitive enhancement by facilitating access to semantic memory structures that are part of long-term memory.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.